Log In
BCIQ
Print this Print this
 

CMV-CTL

  Manage Alerts
Collapse Summary General Information
Company Memorial Sloan Kettering Cancer Center
DescriptionCytomegalovirus (CMV)-specific cytotoxic T lymphocytes
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsTreat anti-viral resistant cytomegalovirus (CMV) following allogeneic hematopoeitic stem cell transplantation (HSCT)
Regulatory Designation
PartnerAtara Biotherapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$33.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/23/2014

Undisclosed

0

$33.0M

Get a free BioCentury trial today